PasitheaLogo.png
Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004
January 18, 2023 08:00 ET | Pasithea
-- Plans to Initiate a Phase 1 Clinical Trial in the U.S. for Neurofibromatosis Type 1 (NF1) in 2H 2023 -- MIAMI BEACH, Fla., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:...
PasitheaLogo.png
Majority of Stockholders Support Pasithea Directors at Special Meeting
December 14, 2022 17:18 ET | Pasithea
MIAMI BEACH, Fla., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and...
PasitheaLogo.png
Pasithea Therapeutics Announces Comprehensive Settlement Agreement with the Camac Group
December 12, 2022 07:00 ET | Pasithea
MIAMI BEACH, Fla., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and...
PasitheaLogo.png
Pasithea Therapeutics to Present at Annual Meeting of the Antibody Society Conference
December 06, 2022 08:00 ET | Pasithea
MIAMI BEACH, Fla., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and...
PasitheaLogo.png
Pasithea Therapeutics Postpones Special Meeting until December 9, 2022 at 9:00 AM Eastern Time
November 28, 2022 19:05 ET | Pasithea
MIAMI BEACH, Fla., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and...
PasitheaLogo.png
Pasithea Therapeutics to Present Tolerizing Vaccine Program Results at Immunotherapy 2022 International Course and Symposium
October 17, 2022 08:00 ET | Pasithea
MIAMI BEACH, Fla., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new...
PasitheaLogo.png
Pasithea Therapeutics Acquires AlloMek Therapeutics
October 12, 2022 08:00 ET | Pasithea
-- Expands CNS Product Portfolio with Addition of CIP-137401, a Macrocyclic, Next-Generation MEK Inhibitor -- Plans to File IND Application with the FDA to Enter the Clinic in 2H 2023 -- Plans to...
PasitheaLogo.png
Pasithea Therapeutics to Call Special Meeting of Stockholders
October 03, 2022 18:03 ET | Pasithea
MIAMI BEACH, Fla., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and...
PasitheaLogo.png
Pasithea Therapeutics Appoints Life Sciences and Health Care Executive Alfred J. Novak to its Board of Directors
September 20, 2022 08:00 ET | Pasithea
MIAMI BEACH, Fla., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and...
PasitheaLogo.png
Pasithea Therapeutics Further Strengthens its Scientific Advisory Board with the Appointment of Dr. Merit Cudkowicz
September 15, 2022 08:00 ET | Pasithea
-- Dr. Cudkowicz is a pioneer in the study and treatment of people with Amyotrophic Lateral Sclerosis (ALS) and other neurological diseases -- MIAMI BEACH, Fla., Sept. 15, 2022 (GLOBE NEWSWIRE) --...